Reevaluation of the microsomal metabolism of montelukast: Major contribution by CYP2C8 at clinically relevant concentrations

Drug Metabolism and Disposition

Volumn 39, Issue 5, 2011, Pages 904-911

  Filppula, Anne M ^a   Laitila, Jouko ^a   Neuvonen, Pertti J ^b   Backman, Janne T ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; MONTELUKAST;

ARTICLE; CONCENTRATION RESPONSE; DEPLETION; DRUG CLEARANCE; DRUG METABOLISM; DRUG OXIDATION; ENZYME ACTIVITY; ENZYME INHIBITION; IN VITRO STUDY; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL;

ACETATES; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYDROXYLATION; ISOENZYMES; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; MICROSOMES, LIVER; MODELS, THEORETICAL; OXIDATION-REDUCTION; QUINOLINES; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 79955033811     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.037689     Document Type: Article

References (36)

1. Backman JT, Honkalammi J, Neuvonen M, Kurkinen KJ, Tornio A, Niemi M, and Neuvonen PJ (2009) CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: Estimation of CYP2C8 half-life using repaglinide as an in vivo probe. Drug Metab Dispos 37:2359-2366.
2. Backman JT, Kyrklund C, Neuvonen M, and Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685-691. (Pubitemid 36021007)
3. Balani SK, Xu X, Pratha V, Koss MA, Amin RD, Dufresne C, Miller RR, Arison BH, Doss GA, Chiba M, et al. (1997) Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile. Drug Metab Dispos 25:1282-1287. (Pubitemid 27490673)
4. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, and Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270.
5. Bourrií M, Meunier V, Berger Y, and Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332. (Pubitemid 27169077)
6. Cheng H, Leff JA, Amin R, Gertz BJ, De Smet M, Noonan N, Rogers JD, Malbecq W, Meisner D, and Somers G (1996) Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res 13:445-448. (Pubitemid 26114730)
7. Chiba M, Xu X, Nishime JA, Balani SK, and Lin JH (1997) Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metab Dispos 25:1022-1031. (Pubitemid 27396488)
8. Crespi CL and Miller VP (1999) The use of heterologously expressed drug metabolizing enzymes-state of the art and prospects for the future. Pharmacol Ther 84:121-131. (Pubitemid 29488547)
9. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
10. Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, and Ball SE (2001) A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 29:23-29. (Pubitemid 32041675)
11. Draper AJ, Madan A, and Parkinson A (1997) Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch Biochem Biophys 341:47-61. (Pubitemid 27198030)
12. Eagling VA, Tjia JF, and Back DJ (1998) Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 45:107-114. (Pubitemid 28045676)
13. Emoto C and Iwasaki K (2007) Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: The effect of the expression of cytochrome b5 with recombinant P450 enzymes. Xenobiotica 37:986-999. (Pubitemid 47482949)
14. Houston JB and Galetin A (2008) Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr Drug Metab 9:940-951.
15. Jaakkola T, Backman JT, Neuvonen M, Niemi M, and Neuvonen PJ (2006) Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone. Eur J Clin Pharmacol 62:503-509.
16. Kajosaari LI, Niemi M, Backman JT, and Neuvonen PJ (2006) Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. Clin Pharmacol Ther 79:231-242.
17. Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, and Backman JT (2010) Gemfibrozil markedly increases the plasma concentrations of montelukast: A previously unrecognized role for CYP2C8 in the metabolism of montelukast. Clin Pharmacol Ther 88:223-230.
18. Kim KA, Park PW, Kim KR, and Park JY (2007) Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans. Br J Clin Pharmacol 63:339-345.
19. Ko JW, Sukhova N, Thacker D, Chen P, and Flockhart DA (1997) Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 25:853-862. (Pubitemid 27318604)
20. Koenigs LL, Peter RM, Thompson SJ, Rettie AE, and Trager WF (1997) Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab Dispos 25:1407-1415. (Pubitemid 28010927)
21. Newton DJ, Wang RW, and Lu AY (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
22. Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M, and Neuvonen PJ (2003a) Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 46:1319-1323. (Pubitemid 37297200)
23. NiemiM, Backman JT, Neuvonen M, and Neuvonen PJ (2003b) Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: Potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46:347-351. (Pubitemid 36547589)
24. Ochiai H, Uchiyama N, Takano T, Hara K, and Kamei T (1998) Determination of montelukast sodium in human plasma by column-switching high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 713:409-414. (Pubitemid 29034669)
25. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, and Parkinson A (2006) Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: Implications for drug-drug interactions. Drug Metab Dispos 34:191-197. (Pubitemid 43042661)
26. Richter T, Mürdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, and Zanger UM (2004) Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 308:189-197. (Pubitemid 38090717)
27. Rostami-Hodjegan A and Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140-148. (Pubitemid 46745341)
28. Schoch GA, Yano JK, Sansen S, Dansette PM, Stout CD, and Johnson EF (2008) Determinants of cytochrome P450 2C8 substrate binding: Structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem 283:17227-17237.
29. Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, and Johnson EF (2004) Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J Biol Chem 279:9497-9503. (Pubitemid 38296017)
30. Stringer RA, Strain-Damerell C, Nicklin P, and Houston JB (2009) Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions. Drug Metab Dispos 37:1025-1034.
31. Tornio A, Niemi M, Neuvonen M, Laitila J, Kalliokoski A, Neuvonen PJ, and Backman JT (2008) The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: Evidence for mechanism-based inhibition of CYP2C8 in vivo. Clin Pharmacol Ther 84:403-411.
32. Venkatakrishnan K, von Moltke LL, Obach RS, and Greenblatt DJ (2003) Drug metabolism and drug interactions: Application and clinical value of in vitro models. Curr Drug Metab 4:423-459. (Pubitemid 37279366)
33. Walsky RL, Gaman EA, and Obach RS (2005a) Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 45:68-78.
34. Walsky RL, Obach RS, Gaman EA, Gleeson JP, and Proctor WR (2005b) Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab Dispos 33:413-418. (Pubitemid 40279942)
35. Wen X, Wang JS, Backman JT, Laitila J, and Neuvonen PJ (2002) Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos 30:631-635. (Pubitemid 34579094)
36. Zhao JJ, Rogers JD, Holland SD, Larson P, Amin RD, Haesen R, Freeman A, Seiberling M, Merz M, and Cheng H (1997) Pharmacokinetics and bioavailability of montelukast sodium (MK- 0476) in healthy young and elderly volunteers. Biopharm Drug Dispos 18:769-777. (Pubitemid 27517566)